We encourage you to read and follow maps.org/safety for information regarding MAPS Code of Ethics for Psychedelic Psychotherapy and our practices to create a culture of safety in the psychedelic community.
You may safely and confidentially submit misconduct reports related to MAPS staff or collaborators to MAPS’ Compliance Team via email.
Participants in clinical trials can report concerns by contacting the study sponsor, found at clinicaltrials.gov, or the Institutional Review Board, found on your study materials.
Statement from MAPS
We have closely examined the facts behind the stories recounted in the recent Business Insider article. We stand behind our work and the work of our independent affiliates Lykos Therapeutics and the Zendo Project. MAPS remains fully supportive of comprehensive, high-quality research, careful analysis of safety and efficacy, and stringent regulatory oversight of any psychedelic-assisted therapy research or delivery.
The article spans four decades and every stage of our growth, from a one-person organization in the 1980’s through today. The bulk of the article is a sensationalized retelling of our story comprised primarily of sensationalized narratives, recycled information already addressed transparently, exaggerated accounts sourced from rumors, and cherry-picked anecdotes.
That being said, MAPS seeks to be remarkably transparent and accountable, so we are closely reflecting on the article to determine if there are concerns raised that we should — and will — address.